TK Choueiri and colleagues evaluated the combination of avelumab, a PD-L1 antibody with axitinib in a Phase 1b clinical trial, where it was not only shown to be safe, but also had 58% objective response rate in patients with metastatic ccRCC [18]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.